CHICAGO — First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy plus pembrolizumab among patients with metastatic triple ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

Once the new combination with sacituzumab govitecan, which targets the Trop-2 protein on tumor cells, is approved, “I would recommend it in the first-line setting,” said Tolaney, a breast ...

CHICAGO -- Treatment with single-agent sacituzumab govitecan (Trodelvy) offered no survival advantage over docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated ...

Background: Sacituzumab govitecan (SG) is approved for the treatment of metastatic triple-negative breast cancer in the ≥2 treatment line setting, with a standard dosage of 10 mg/kg IV on Days 1 and 8 ...

Sacituzumab govitecan links an anti-Trop-2 antibody to SN-38, one of the chemotherapy drugs used to kill cancer cells in triple-negative breast cancer [3].

WEDNESDAY, Aug. 14, 2024 (HealthDay News) -- For patients with advanced endometrial cancer (EC), sacituzumab govitecan (SG), a trophoblast cell-surface antigen 2 (Trop-2)-directed antibody-drug ...

The drug Trodelvy (drug name sacituzumab govitecan-hziy) is showing promise for first-line metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors (treatments ...

CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the 'Company') today announced that results from the Phase 1/2 study (KL264-01/MK-2870-001) evaluating ...

Gilead is continuing to explore sacituzumab govitecan in other phase 3 trials, including ASCENT-07 (ClinicalTrials.gov Identifier: NCT05840211) for hormone receptor–positive, human epidermal ...